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Abstract: BACKGROUND: Chronic urticaria affects patients by interfering with their daily activities, damaging their self-esteem
and negatively affecting their interpersonal relationships.  Healthcare professionals may underestimate the impact of the con-
dition on patients’ quality of life.  
OBJECTIVES: To evaluate quality of life using one generic and one disease-specific health-related quality of life instrument; to compare
quality of life between the different clinical types of chronic urticaria and to evaluate whether angioedema further impairs quality of life.  
METHODS: Sixty-two patients with chronic urticaria, who had had signs or symptoms of the disease within the preceding week, were
divided into groups according to whether they had ordinary chronic urticaria, physical chronic urticaria or mixed chronic urticaria.  
RESULTS: There was a predominance of women in this study (72.6%).  The mean age of patients was 39.8 years and angioede-
ma was associated with chronic urticaria in 75.8% of cases.  Associated angioedema was more commonly found in patients with
ordinary chronic urticaria (p=0.011) and in women (p=0.024).  With respect to the different clinical types, 32.3% of the
patients had ordinary chronic urticaria, 27.4% had physical chronic urticaria and 40.3% had mixed chronic urticaria.  Mean
overall score for the disease-specific questionnaire was 10.4.  In this questionnaire, the most affected domains were “symptoms
and feelings” and “daily activities”, while the most affected domains in the SF-36 were “physical role” and “vitality”.  Quality of
life was found to be impaired in women, in patients of up to 30 years of age, in those attending a first consultation, in those
with higher education levels, in patients who had had the disease for up to one year and in those with angioedema.  
CONCLUSIONS: Chronic urticaria affects quality of life, as measured using a disease-specific questionnaire and a generic ques-
tionnaire.  There was no statistically significant difference between the clinical types.  The presence of angioedema impaired
patients’ quality of life even further.  There was a statistically significant correlation between the scores obtained using the
disease-specific questionnaire and those obtained using the generic questionnaire. 
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Resumo: FUNDAMENTOS: A urticária crônica compromete o doente por interferir nas atividades diárias, prejudicar a autoesti-
ma e as relações interpessoais. Os profissionais de saúde subestimam seu impacto na qualidade de vida dos doentes. 
OBJETIVOS: Avaliar a qualidade de vida com questionário específico e genérico. Compará-la entre os tipos clínicos de urticária
crônica e avaliar se o angioedema piora a qualidade de vida. 
MÉTODOS: Participaram 62 doentes com urticária crônica, com sinais e sintomas da doença até 7 dias da consulta, que foram
divididos em urticária crônica comum, urticária crônica física e urticária crônica mista. 
RESULTADOS: Observou-se predominância de mulheres (72,6%), idade média de 39,8 anos, angioedema associado em 75,8%
dos doentes. Apresentaram mais angioedema doentes com urticária crônica comum (p=0,011) e mulheres (p=0,024).
Quanto aos tipos clínicos, 32,3% apresentaram urticária crônica comum, 27,4% urticária crônica física e 40,3% urticária crôni-
ca mista. O escore médio total do questionário específico foi 10,4. No questionário específico, os domínios mais comprometi-
dos foram “Sintomas e sentimentos” e “Atividades diárias”, e, no SF-36, “Aspectos físicos” e “Vitalidade”. Houve comprometi-
mento da qualidade de vida nas mulheres, nos doentes com até 30 anos, em primeira consulta, nos mais escolarizados,
naqueles com até 1 ano de doença e naqueles com angioedema. 
CONCLUSÕES: A urticária crônica compromete a qualidade de vida medida pelos questionários específico e genérico. Não houve
 diferença estatisticamente significante na qualidade de vida entre os tipos clínicos. A presença do angioedema conferiu pior qualidade de
vida aos doentes. Houve correlação estatisticamente significante entre os escores do questionário específico e do questionário genérico.
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INTRODUCTION
Urticaria is a common disease that is character-
ized by transient pruriginous wheals that may be
accompanied by angioedema. 1,2 Diagnosis is eminent-
ly clinical and meticulous anamnesis is essential to
establish the clinical form of the disease and the pos-
sible causative agent. 3,4
The condition is considered chronic when
wheals are present on a daily or almost daily basis for
a period exceeding six weeks. 1,2,5-7 In this form, the
disease often interferes with the patient’s routine
activities, damaging his/her self-esteem and negatively
affecting interpersonal relationships. 6,8
Since the course of the disease is benign from a
clinical point of view and it is non-life threatening,
with transitory lesions and temporary disfigurement,
healthcare professionals often underestimate the
impact of chronic urticaria on patients’ quality of life. 9
Currently, there appears to be a trend in the
medical literature towards recognizing and under-
standing the impact of skin diseases on patients’ qual-
ity of life.  In recent decades, various instruments have
been developed to measure quality of life in dermatol-
ogy with the objective of evaluating patients’ progress
and understanding in what ways the disease affects
them. 10-13
The impact of a disease on quality of life may
not be directly related to its clinical severity but rather
with the resulting stigmatization and the discomfort it
causes, reinforcing the importance of quality of life
studies in dermatology. 11,14
Studies have shown that the degree to which
quality of life is affected in patients with chronic
urticaria may vary in accordance with the different
clinical types of the disease, and may in some aspects
even become disabling. 15 The degree to which quali-
ty of life is impaired in these patients was found to be
similar to that experienced by coronary patients with
triple vessel coronary artery disease, principally with
respect to psychological aspects and social relation-
ships. 9
The objective of the present study was to assess
the impact of chronic urticaria on patients’ quality of
life and to clarify which domains were more severely
affected in these patients.  To do so, two question-
naires were applied that had already been validated
and culturally adapted for use in Brazil: the Medical
Outcomes Study 36-item short-form health survey (SF-
36), a generic instrument, and the Dermatology Life
Quality Index (DLQI) a disease-specific instrument.
16,17 Whereas the DLQI deals with quality of life by
directly addressing the components that are most like-
ly to be affected in patients with skin diseases, the SF-
36 deals with quality of life generically, incorporating
all the domains considered important in measuring
the general concept of quality of life.
MATERIAL AND METHODS
The sample consisted of male and female
patients of 18 years of age or more, diagnosed with
chronic urticaria associated or not with angioedema,
who were selected at the urticaria outpatient clinic of
the Dermatology Department, Escola Paulista de
Medicina (EPM), University of São Paulo (UNIFESP),
São Paulo, Brazil.  The study was approved by the
institution’s internal review board under reference
number 0526/07.
Sixty-two patients with chronic urticaria were
evaluated and classified into three groups in accor-
dance with an adapted version of the clinical classifi-
cation established by Grattan et al.3:
Chronic ordinary urticaria (COU) (n = 20)
Physical urticaria (PU) (n = 17)
Mixed urticaria (MU) (n = 25), a definition
established in this study to define patients in whom
the two forms of urticaria (COU and PU) coexisted.
Patients in whom lesions had not been present
over the preceding week, those with a diagnosis of
acute urticaria, contact urticaria, urticarial vasculitis,
angioedema without wheals, patients unable to
understand the terms of the study and to provide their
written consent to participate and patients with asso-
ciated clinical and/or psychiatric comorbidities were
not included in the study.
Participation was voluntary following consulta-
tion at the outpatient urticaria clinic and after the
patient had signed an informed consent form.
Patients with university education read and answered
the questionnaires independently.  The investigator
was available throughout the entire time to answer
any questions.  In the case of patients with other lev-
els of education, the investigator read the questions
aloud and ticked the participants’ answers in the ques-
tionnaires.  It should be emphasized that both ques-
tionnaires permit this form of application, although it
is known that it may affect the answers obtained.
Portuguese language versions of the SF-36 and
DLQI were used. 16,17 The SF-36 is a generic instru-
ment that evaluates quality of life over the previous
four weeks.  The questionnaire was developed by
Ware and Sherbourne in 1992.  It is simple to admin-
ister and consists of 36 questions grouped into eight
domains: Physical Functioning, Role-Physical, Bodily
Pain, General Health, Vitality, Social Functioning,
Role-Emotional and Mental Health. 18 Each domain is
awarded its own score, which ranges from 0 to 100 in
which 0 represents the poorest state of health and 100
the best state.  The lower the score, the more the indi-
vidual’s quality of life is affected.
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The DLQI is a questionnaire used specifically in
dermatology, which was developed by Finlay and
Khan in 1994.  It is designed to measure the impact of
skin conditions on quality of life. 10 It is composed of
ten questions, which can be subdivided into six
domains: symptoms and feelings, daily activities,
leisure, work/school, personal relationships and treat-
ment.  It may be interpreted as a total score or in
accordance with the scores of each individual domain.
The total DLQI score is calculated from the sum of the
scores awarded to each question and ranges from 0 to
30 in which 0 represents the best state of health and
30 the poorest state.  The higher the score, the more
the quality of life of the individual is affected.  This
questionnaire evaluates quality of life over the previ-
ous seven days, a period that is sufficiently short so as
to facilitate recall.  Authorization to use the question-
naire was obtained from its authors. [1]
The data were analyzed using the SPSS statisti-
cal software program, version 10.0.  Descriptive analy-
sis was used for the clinical and demographic charac-
teristics of the patients studied, while the chi-square
test was used to compare categorical data, Student’s t-
test was used to compare two independent means and
analysis of variance (ANOVA) was used to compare
three or more independent means, together with
Tukey’s test for multiple comparisons.  Spearman’s
correlation coefficient (r) was used to evaluate the
association between the continuous variables.
Probability (p) < 0.05 was used to indicate statistical
significance.
RESULTS
Sociodemographic data and clinical types
of chronic urticaria
Sixty-two patients were enrolled to this study.
The mean age of the patients was 39.8 ± 12 years
(mean ± SD) and the majority (72.6%) was female.
Only a small percentage of these patients (17.7%) had
university education.  With respect to the duration of
the disease as reported by the patients themselves,
32.3% were found to have had the condition for 1-5
years, while 30.6% reported having had urticaria for
more than five years.  Patients included those attend-
ing their first consultation and those who were
already being followed up prior to the study.  More
than half the patients (51.6%) were attending their
first consultation (Table 1).
With respect to the clinical types of chronic
urticaria, 32.3% of patients had COU, while 27.4% had
PU and the majority (40.3%) had MU (Table 1).
There was no statistically significant difference
between the three clinical types with respect to age,
gender, duration of the disease or duration of follow-
up at the clinic.
Angioedema was associated with the course of
chronic urticaria in 75.8% of patients.  The patients
with COU were more likely to have angioedema than
those with PU (90.0% versus 52.9%; p = 0.011) and
women were more likely to have angioedema than
men (84.4% versus 52.9%; p = 0.024).
Evaluation of quality of life
DLQI:  The mean overall score in the DLQI was
10.4 ± 7.7.  The domains indicative of greater impair-
ment of quality of life were symptoms and feelings
(3.2 ± 1.9) and daily activities (2.6 ± 2.3) (Table 2).
SF-36:  The domains indicative of greater
impairment of quality of life were:  role-physical
(55.70 ± 45.60) and vitality (60.20 ± 27.90).  The
least affected were social functioning (78.50 ± 24.00)
and bodily pain (68.70 ± 27.40) (Table 2).
Quality of life and clinical types
No statistically significant differences were
found between the three clinical types (COU, PU, MU)
in either of the instruments evaluated with respect to
quality of life.
Age (SD/range) (years) 39.8 ± 12/18-74
≤ 30 years (%) 25.8
31-45 years (%) 43.5





Primary school (%) 38.7
Secondary school (%) 43.5
University (%) 17.7
Duration of the disease 43.5 ± 50.8/ 2-256
(SD/range) (months) 
6 weeks - 1 year (%) 37.1
1 - 5 years (%) 32.3
> 5 years (%) 30.6
Time in outpatient clinic 15.4 ± 27.3/0-136
(SD/range) (months)
First consultation (%) 51.6
1 -20 months (%) 24.2
>21 months (%) 24.2
Clinical types of chronic urticaria
Chronic ordinary urticaria (%) 32.3
Physical urticaria (%) 27.4
Mixed urticaria (%) 40.3
TABLE 1: General characteristics of the 62 patients
and the frequency of the three clinical types of
chronic urticaria
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Quality of life and gender
Quality of life was found to be more affected in
women, with statistically significant differences com-
pared to men in the daily activities domain of the
DLQI (p=0.003) and in the vitality (p=0.038), role-
emotional (p=0.018) and mental health (p=0.020)
domains of the SF-36.
Quality of life and age
In patients of up to 30 years of age, quality of
life was only found to be affected in the DLQI, with a
statistically significant difference in the daily activities
domain (p=0.033).
Quality of life and education level
According to both questionnaires, quality of
life was better in the case of patients with only pri-
mary education.  In the DLQI, the domains with statis-
tically significant differences were daily activities
(p=0.017) and leisure (p=0.001), as well as the over-
all score (p=0.037), while in the SF-36, a statistically
significant difference was found only in the social
functioning domain (p=0.029).
Quality of life and duration of the disease
The patients with up to one year of the disease
had poorer quality of life scores, with statistically sig-
nificant differences in the following domains of the
DLQI: leisure (p=0.018), personal relationships
(p=0.003) and overall score (p=0.013) but only in
the social functioning domain of the SF-36 (p=0.010).
Quality of life and duration of follow-up at
the outpatient clinic
Patients attending for their first consultation
had poorer quality of life scores compared to the
other patients, with statistically significant differences
in the following domains of the DLQI: symptoms and
feelings (p=0.001), work/school (p=0.042), personal
relationships (p=0.025) and overall score (p=0.004),
but only in the role-physical domain of the SF-36
(p=0.036).
Quality of life and angioedema
The patients with chronic urticaria and
angioedema scored worse in the domains of the SF-36
compared to the patients without angioedema, with
statistically significant differences for general health
(p=0.002), mental health (p=0.016) and vitality
(p=0.050).  No differences were found in the DLQI. 
Correlations
Table 3 shows the calculations of Spearman’s
correlations (r) between the domains of the DLQI and
those of the SF-36.  All the statistically significant cor-
relations between the two questionnaires were nega-
tive and found to be weak to moderate, with an r of -
0.254 to -0.465.
DISCUSSION
Quality of life is an ample and subjective con-
cept that is dependent on a cultural, social and envi-
ronmental context.  It was defined by the World
Health Organization as an “individual’s perception of
their position in life in the context of the culture and
value systems in which they live and in relation to
their goals, expectations, standards and concerns”. 19
Since it is a multidimensional concept, the term
health-related quality of life was coined.  This corre-
sponds to a more limited notion of quality of life,
encompassing the domains directly associated with
states of physical, psychological and social health. 20,21
Objective measurements of health status are
important in defining the degree of health; however,
it is the individual’s own perception of his/her state of
health that reflects their true quality of life.  Ability to
deal with limitations and disabilities may greatly affect
the individual’s perception of his/her state of health
and consequently his/her satisfaction with life.
Therefore, two people with the same state of health
may experiment different quality-of-life status. 22
What makes the study of quality of life original
is the fact that it attempts to measure the needs of an
individual based on his/her own perceptions, not just
the perceptions of their physician.  Conditions consid-
ered benign by physicians may have an immense
repercussion on patients’ lives just as diseases that are
potentially serious may not exert an immediate effect
on the patient’s quality of life.  Therefore, taking the
patients’ expectations into consideration in selecting
Mean ± SD
DLQI – Overall score 10.4 ± 7.7
DLQI – Score in each domain
Symptoms and feelings 3.2 ± 1.9
Daily activities 2.6 ± 2.3
Leisure 1.7 ± 1.8
Work/school 0.7 ± 1.1
Personal relationships 1.5 ± 2.1
Treatment 0.8 ± 1.1
SF-36 – Score in each domain
Physical Functioning 78.50 ± 24.00
Role-Physical 55.70 ± 45.60
Bodily Pain 68.70 ± 27.40
General Health 66.20 ± 23.70
Vitality 60.20 ± 27.90
Social Functioning 64.70 ± 33.30
Role-Emotional 62.40 ± 45.40
Mental Health 62.40 ± 24.10
TABLE 2: DLQI and SF-36 – Mean scores of the 62
patients with chronic urticaria
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a therapeutic strategy optimizes the doctor-patient
relationship. 22
Skin diseases potentially exert a negative effect
on patients’ quality of life. 21 They may impair quality
of life to the same degree as more debilitating diseases
or those in which the risk to life is greater.  The degree
of involvement may not correlate with the clinical
severity of the disease, but may present as psycholog-
ical stress, embarrassment, stigmatization or physical
discomfort that over time may result in a significant
decrease in emotional and social well being and in
productivity at school or at work. Altogether, these
factors may significantly affect the course of the dis-
ease and the patient’s response to the proposed ther-
apeutic interventions. Therefore, it is essential that
the dermatologic evaluation include measurements of
the patients’ perception of their well-being in relation
to the skin disease, i.e. quality of life assessments.  11,23
When dealing with the patient with chronic
urticaria it is important to emphasize that the cause of
the disease may remain undetermined and that
response to treatment may be disappointing. 6 The
patient’s frustration may result in a decrease in his/her
quality of life.  The objective of treatment should be to
control the chronic urticaria so as to minimize its
effect on the patient’s quality of life.
The objective of this study was to evaluate the
impact of chronic urticaria on patients’ quality of life
and clarify in which domains patients feel more affect-
ed by the disease.
Analysis of the SF-36 and DLQI scores showed
that chronic urticaria is a disease that impairs quality
of life.  Other studies based on the same instruments
have shown similar results. 15,24-27
The patients selected for this study were
recruited at a dermatology outpatient clinic specializ-
ing in urticaria. The clinic is linked to a university that
is a reference in tertiary healthcare.  Consequently, it
is probable that the degree of morbidity found may be
greater and may not be representative of patients with
chronic urticaria in the general population.  This may
justify the greater negative impact on quality of life
found in the present study.  Furthermore, the majori-
ty of the population referred to public healthcare serv-
ices is generally found to be economically deprived, a
situation that may generate variables capable of affect-
ing quality of life, either for the better or for the worse,
depending on the aspect analyzed.
Some variance was observed in the comparison
between the overall mean score of the DLQI in the
present study (10.4) and data published in the litera-
ture.  The mean scores reported in the literature range
from 5.1 to 13.4. 25,28-30 The forms of data collection
(interview or self-administration, randomized sam-
ples, treated or untreated patients) and the cultural
differences of the patients studied (education level,
subjectivity of the suffering) may explain these differ-
ences.  In the present study, the most affected
domains of quality of life were symptoms and feelings
and daily activities.  Both represent the areas in which
the signs and symptoms of the disease would have the
greatest repercussion.  The symptoms and feelings
domain reflects how pruritus and the presence of
wheals may upset or embarrass the patient in front of
other people.  The daily activities domain shows how
chronic urticaria may hamper the patient’s daily life or
restrict their manner of dressing.  These findings are
in agreement with data published in the literature.
15,28,30
In the present study, the SF-36 domains indica-
tive of greater impairment of quality of life were: role-
physical and vitality.  The role-physical domain reflects
An Bras Dermatol. 2011;86(5):897-904.
PF RP Pain GH Vit Soc F R Emot MH
Symptoms and feelings r-0.317 -0.426 -0.355 -0.465 -0.333 -0.441 -0.236 -0.357
p0.012 0.001 0.005 0 0.008 0 0.065 0.004
Daily activities r-0.254 -0.341 -0.299 -0.344 -0.382 -0.234 -0.217 -0.314
p0.046 0.007 0.018 0.006 0.002 0.067 0.09 0.013
Leisure r-0.248 -0.358 -0.295 -0.410 -0.274 -0.401 -0.205 -0.270
p0.052 0.004 0.02 0.001 0.031 0.001 0.11 0.034
Work/school r-0.169 -0.385 -0.258 -0.280 -0.164 -0.260 -0.184 -0.167
p0.19 0.002 0.043 0.027 0.203 0.041 0.151 0.195
Personal relationships r-0.213 -0.465 -0.12 -0.342 -0.245 -0.333 -0.23 -0.344
p0.096 0 0.352 0.007 0.055 0.008 0.073 0.006
Treatment r-0.042 -0.366 -0.258 -0.281 -0.316 -0.298 -0.165 -0.155
p0.752 0.004 0.048 0.031 0.015 0.022 0.213 0.241
TABLE 3: Spearman’s correlation between the domains of the DLQI and those of the SF-36 with respect 
to the 62 patients with chronic urticaria
PF = physical functioning / RP = role-physical / GH = general health / Vit = vitality / Soc F= social functioning / 
R Emot = role-emotional / MH = mental health
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the repercussion of possible limitations of physical
health in carrying out work-related and daily activi-
ties.  The vitality domain evaluates the individual’s
energy level and fatigue.  This result was expected,
since it shows the extent to which pruritus and the
anguish provoked by this condition, as well as the
skin lesions, may hamper the patient in carrying out
work-related activities, either by reducing the individ-
ual’s attention level or as a result of the discomfort
and irritability these conditions cause.  The least
affected domains were physical functioning and bodi-
ly pain.  The physical functioning domain measures
the repercussion of possible physical limitations on
daily activities such as taking a bath, dressing, walking
moderate distances, running, climbing stairs, carrying
bags, bending over and kneeling.  The bodily pain
domain evaluates the effect of possible pain on daily
and work-related activities.  Therefore, it is expected
that these domains would be affected to a lesser
extent in chronic urticaria with no other associated
comorbidities.  Reports in the literature reflect a sim-
ilar pattern. 24,26
In the comparison of the scores of the ques-
tionnaires between the clinical types of chronic
urticaria (COU, PU and MU), no statistically significant
differences were found between the various types and
it was impossible to conclude whether one may affect
quality of life to a greater extent than another.  In the
literature, O’Donnel et al. (1997) and Poon et al.
(1999) described poorer quality of life in patients with
delayed pressure urticaria and cholinergic urticaria.
9,15 In both these studies, sample sizes were larger
than that of the present study.  We believe that a larg-
er sample would permit a similar conclusion to be
reached, since in our clinical practice the suffering of
the patients with these forms of physical urticaria is
perceptible.
Women suffer the impact of chronic urticaria
more than men.  In the DLQI, a statistically significant
difference was found only in the daily activities
domain (p=0.003).  This domain is composed of
questions that evaluate difficulties in going shopping
or taking care of the house and to what extent the
state of the patient’s skin affects his/her choice of
clothing.  Therefore, it is possible that this domain
may involve situations that lead to greater negative
repercussions on women.  In the SF-36, the effects on
quality of life in the vitality, role-emotional and men-
tal health domains were statistically significant
(p=0.038, p=0.018, p=0.020, respectively).  This
indicates a possible psychological and emotional vul-
nerability in women coping with chronic urticaria.
The domains that were affected measure the energy
and fatigue levels reported by the patients, the reper-
cussion of possible emotional disturbances on the
individual’s ability to work, and possible states of anx-
iety and depression.  An evaluation of psychiatric
comorbidities associated with the patient’s dermato-
logical status would be useful to identify whether
these results were exclusively a consequence of the
repercussions of chronic urticaria on these patients’
quality of life.
In the patients of up to 30 years of age, the daily
activities domain (p=0.033) of the DLQI was signifi-
cantly more affected.  As this domain includes a ques-
tion related to clothing, younger patients may feel
more severely affected by this limitation compared to
older patients.
Patients with a better education level were
more affected than those with less schooling.  There
was a statistically significant difference in the daily
activities (p=0.017) and leisure domains (p=0.001)
and in the overall score (p=0.037) of the DLQI, as
well as in the social functioning domain of the SF-36
(p=0.029).  It is possible that better-educated individ-
uals are more affected by pruritus and wheals than
individuals with less schooling because they have a
better understanding of the situation they are experi-
encing but are less willing to accept it.
Quality of life was more affected in the patients
who had had the disease for up to one year according
to both questionnaires, principally in the domains
related to social activities and personal relationships.
Statistically significant differences were found in the
leisure (p=0.018) and personal relationships domains
(p=0.003) and in the overall score (p=0.013) of the
DLQI and in the social functioning domain of the SF-
36 (p=0.010), indicating more intense suffering in the
case of these patients.  These results highlight the
degree to which the social life of patients with chron-
ic urticaria is affected: the limitations imposed on
their leisure activities because of embarrassment or
fear of triggering the disease and the negative effect
on their relationships that predisposes them to social
isolation.  Furthermore, the patient who has had the
disease for only a short time is confronting a novel sit-
uation and tends to assume a less conformist attitude
with respect to the disease.
Patients at their first consultation, i.e. those
defined as not being followed up as outpatients at the
time of the interview, had poorer quality of life.  In the
DLQI, the differences were statistically significant both
with respect to the overall score (p=0.004) and in the
symptoms and feelings (p=0.001), work/school
(p=0.042) and personal relationships (p=0.025)
domains.  The SF-36 revealed significant impairment
only in the role-physical domain (p=0.036).  Half the
present sample consisted of patients attending their
first consultation at the urticaria clinic.  This suggests
that many of these patients still had a poor under-
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standing of how to control the disease, of treatment
and of what triggers chronic urticaria.  Some were not
yet undergoing any treatment at all.  This certainly
contributed to this negative impact on quality of life.
Angioedema during the course of chronic
urticaria resulted in poorer quality of life in these
patients.  Those with associated angioedema had
poorer scores, with statistically significant differences
in the general health (p=0.002), mental health
(p=0.016) and vitality (p=0.050) domains of the SF-
36 compared to the patients without angioedema.  In
a study conducted by Poon et al. (1999)15, the associa-
tion of angioedema with chronic urticaria did not
worsen patients’ quality of life.  Angioedema during
chronic urticaria, although benign, is disfiguring.  It is
understandable that the intense embarrassment
caused by this condition could have a negative effect
on the patient’s quality of life.  
All the significant correlations in the DLQI and
SF-36 scores were negative, with the majority being
weak to moderate.  Bearing in mind that the scores of
the two questionnaires are read in opposite direc-
tions, negative correlations are to be expected.
Whereas in the DLQI higher scores represent poorer
quality of life, in the SF-36 questionnaire higher scores
are indicative of better quality of life.  These signifi-
cant correlations, albeit only moderate to weak, show
that both questionnaires deal with the same topic in a
complementary way; however, one does not substi-
tute the other.  Whereas the DLQI deals with quality of
life, focusing more directly on the components that
are more likely to be affected in patients with skin dis-
eases, the objective of the SF-36 is to treat quality of
life generically, encompassing domains considered
important for measuring the general concept of qual-
ity of life.  The correlations between the question-
naires may be interpreted as a validation test, i.e. to
assess whether the SF-36 is appropriate for the meas-
urement of quality of life in patients with skin diseases
in various areas.
CONCLUSION
In recent years, there has been a growing trend
towards valuing the patient’s perception of the effect
of his/her disease on their state of health.  Therefore,
instruments that evaluate quality of life have emerged
as parameters to measure the different components
that constitute health status, complementing the tradi-
tional parameters of evaluating diseases and treat-
ments.  Use of these instruments to measure quality of
life should not be restricted to research studies, but
should also be considered in routine clinical practice,
with a periodic evaluation of the quality of life of
patients undergoing outpatient follow-up.  
In patients with chronic urticaria, quality of life
is negatively affected, as measured by both the DLQI
and SF-36 questionnaires.   There was no statistically
significant difference between the clinical types of the
disease.  Angioedema during the course of chronic
urticaria had a negative effect on patients’ quality of
life.  Quality of life was poorer and this difference was
statistically significant in: patients of up to 30 years of
age, patients with higher education levels, patients
with up to one year of the disease and patients attend-
ing their first consultation at the clinic.
The study was based on the observation of dif-
ferent degrees of disability found in patients at the
urticaria outpatient clinic of the Dermatology
Department, UNIFESP.   Some patients, even those
with more severe clinical forms of the disease, paid lit-
tle heed to the pruritus and wheals and did not feel at
all stigmatized.  On the other hand, other patients
reported mild forms of the disease as being restrictive
and intolerable.  Therefore, it is important to evaluate
quality of life in chronic urticaria and principally to
understand the perception of these patients in rela-
tion to their state of health and to their physical and
psychosocial limitations in order to establish optimal
humane and pharmacological management in each
individual case.
The principal areas in which the quality of life
of patients with chronic urticaria is impaired involve
psychological aspects and social relationships.  A dis-
cussion on the possible psychiatric comorbidities
associated with chronic urticaria is outside the scope
of the present study; however, the need to associate
psychological care with skin treatment in certain cases
is undeniable, either because of psychological damage
resulting from the limitations imposed by chronic
urticaria or because of psychiatric comorbidities that
may have preceded the skin disease.
Another important objective of the present
study was to alert healthcare professionals to these
patients.  As understanding increases of how chronic
urticaria affects quality of life, medical decisions are
coming closer to the perspectives of the patients with
respect to their disease and its treatment.  This broad-
ens the scope of the doctor-patient relationship, con-
sequently rendering it more humane.  Therefore, eval-
uations of quality of life are becoming established as
an integral part of treatment; however, further studies
are required to fully clarify the pathogenesis of chron-
ic urticaria so that new therapeutic strategies can be
developed, reducing the extent to which the quality of
life of these patients is impaired by this disease. ❑
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